Non-invasive evaluation of liver stiffness in nonalcoholic fatty liver disease: supersonic shear imaging, FibroScan or ARFI?

Non-invasive evaluation of liver stiffness in nonalcoholic fatty liver disease: supersonic shear imaging, FibroScan or ARFI?

We have read the article by Cassinotto et al. with interest in a recent issue of the Hepatology. They concluded that Acoustic elastic radiation force impulse (ARFI), FibroScan (FS) and Supersonic Shear Imaging (SSI) were useful tools to stage the severity of fibrosis in patients with non-alcoholic f...

Full description

Bibliographic Details
Main Authors:	Coskun Ozturker, Ergenekon Karagoz, Ersin Ozturk
Format:	Article
Language:	English
Published:	Society of Turaz Bilim 2016-12-01
Series:	Medicine Science
Subjects:	liver disease nonalcoholic fatty fibroscan
Online Access:	http://www.ejmanager.com/fulltextpdf.php?mno=226076

Similar Items

Performance of liver stiffness measurements obtained with FibroScan is affected by glucose metabolism in patients with nonalcoholic fatty liver disease
by: Xinyu Yang, et al.
Published: (2021-03-01)

Accuracy of Liver Fibrosis Degree Based on King’s Score to FibroScan in Chronic Hepatitis B
by: Yudi Andre Marpaung, et al.
Published: (2016-05-01)

Liver Stiffness Measurement by Fibroscan in Patients With Hepatitis B
by: Ali Bahari, et al.
Published: (2021-01-01)

Prediction of oesophageal varices in cirrhotic patients by measuring liver stiffness with fibroscan
by: Shahinul Alam, et al.
Published: (2016-08-01)

Liver Stiffness Measurement by Fibroscan Predicts the Presence and Size of Esophageal Varices in Egyptian Patients with HCV Related Liver Cirrhosis
by: Yasmin Saad, et al.
Published: (2013-10-01)

The feasibility of using liver function indices and FibroScan in combination to predict the occurrence of anti-tuberculosis drug-induced liver injury in Patients with liver disease
by: Shaoqiang Wu, et al.
Published: (2025-01-01)

Diagnostic value of Transient Elastography (Fibroscan) in the evaluation of liver fibrosis in chronic viral hepatitis C: Comparison to liver biopsy
by: Mona El-Hariri, et al.
Published: (2017-06-01)

FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran
by: Behnaz Amernia, et al.
Published: (2021-12-01)

AST/ALT ratio, APRI, and FIB-4 compared to FibroScan for the assessment of liver fibrosis in patients with chronic hepatitis B in Bandar Abbas, Hormozgan, Iran
by: Seyed Hamid Moosavy, et al.
Published: (2023-05-01)

Effect of FibroScan test in antiviral therapy for HBV-infected patients with ALT <2 upper limit of normal
by: Han Xian-Zhi, et al.
Published: (2020-06-01)

Effect of 48‐week pemafibrate on non‐alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan‐aspartate aminotransferase score
by: Takeshi Hatanaka, et al.
Published: (2021-10-01)

Diagnostic Performance of Ultrasonography in Detecting Fatty Liver Disease in Comparison with Fibroscan in People Suspected of Fatty Liver
by: Leila Kamali, et al.
Published: (2019-01-01)

Prevalence of clinically relevant liver fibrosis due to nonalcoholic fatty liver disease in Indian individuals with type 2 diabetes
by: Mohammad Shafi Kuchay, et al.
Published: (2021-08-01)

The Combination of Noninvasive Tests and Fibroscan for the Assessment of Liver Fibrosis among Patients with Nonalcoholic Fatty Liver Disease
by: Muntadher Abdullah, et al.
Published: (2023-12-01)

Nonalcoholic fatty liver scoring panels shortcut for fibro scanning results or not
by: Saba Fakhrieh Asl, et al.
Published: (2023-12-01)

2D shear wave elastography (SWE) performance versus vibration-controlled transient elastography (VCTE/fibroscan) in the assessment of liver stiffness in chronic hepatitis
by: Ahmed M. Osman, et al.
Published: (2020-03-01)

The discriminatory ability of FibroScan liver stiffness measurement, controlled attenuation parameter, and FibroScan–aspartate aminotransferase to predict severity of liver disease in children
by: Alexander Chaidez, et al.
Published: (2022-11-01)

Noninvasive diagnosis of nonalcoholic fatty liver disease
by: Robert P. Myers
Published: (2009-01-01)

NON-INVASIVE ASSESSMENT OF LIVER FIBROSIS USING LIVER ELASTOGRAPHY (FIBROSCAN) IN PATIENTS WITH CHRONIC INFECTION HBV AND HCV
by: Andreea Rădășan, et al.
Published: (2016-09-01)

Correlación entre los hallazgos tomográficos y los resultados obtenidos por FibroScan® para la detección de esteatosis hepática.
by: Pablo Aure Celli, et al.
Published: (2024-12-01)

Rendimiento diagnóstico del FibroScan en un centro de enfermedades hepáticas en Bogotá durante el 2019 al 2022
by: Diana del Pilar Torres Pabón, et al.
Published: (2024-03-01)

Fibroscan versus liver biopsy in the evaluation of response among the Egyptian HCV infected patients to treatment
by: Sherif El Saadany, et al.
Published: (2016-03-01)

Diffusion-weighted MRI and fibroscan vs. histopathology for assessment of liver fibrosis in chronic HCV patients: (Pilot study)
by: Ahmed Hosni Kamel Abdelmaksoud, et al.
Published: (2015-06-01)

Predicting cardiometabolic disease in medical students using FibroScan and 30-year Framingham risk scores
by: Charu Sharma, et al.
Published: (2024-09-01)

A New Endemic of Concomitant Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B
by: Hira Hanif, et al.
Published: (2020-10-01)

Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Evaluation of Hepatic Fibrosis and Steatosis Using Fibroscan
by: Tran Thi Khanh Tuong, et al.
Published: (2020-03-01)

THE EVALUATION OF HEPATIC FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C, USING THE FIBROMAX AND FIBROSCAN TECHNIQUES
by: Iulia Anca Marian (Deaconu), et al.
Published: (2018-12-01)

Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease
by: Eddowes, P, et al.
Published: (2019)

A scientifically validated combination of garcinol, curcuminoids, and piperine for mild to moderate nonalcoholic steatohepatitis patients—results from a randomized, double-blind, placebo-controlled study
by: Muhammed Majeed, et al.
Published: (2023-12-01)

Correlation between Liver function tests, lipid profile and fibroscan in non-alcoholic fatty liver disease
by: Ali A. Ghweil, et al.
Published: (2023-01-01)

Nonalcoholic Fatty Liver Disease, Liver Fibrosis and Cardiovascular Disease in the Adult US Population
by: Stefano Ciardullo, et al.
Published: (2021-07-01)

Effect of Meal Ingestion on Liver Stiffness and Controlled Attenuation Parameter
by: Marco Silva, et al.
Published: (2018-04-01)

Non-invasive assessment of liver fibrosis with transient elastography (FibroScan®): applying the cut-offs of M probe to XL probe
by: Grace Lai-Hung Wong, et al.
Published: (2013-07-01)

Comparison of Transient Elastography and Point Shear Wave Elastography for Analysis of Liver Stiffness: A Prospective Study
by: Giuseppe Losurdo, et al.
Published: (2024-03-01)

EVALUAREA FIBROZEI HEPATICE CU AJUTORUL TEHNICILOR FIBROMAX ŞI FIBROSCAN LA PACIENŢII CU HEPATITĂ CRONICĂ C
by: Iulia Anca Marian, et al.
Published: (2018-12-01)

Validation of Controlled Attenuation Parameter Measured by FibroScan as a Novel Surrogate Marker for the Evaluation of Metabolic Derangement
by: Zhimin Huang, et al.
Published: (2022-01-01)

Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease
by: Ankur Srivastava, et al.
Published: (2019-07-01)

Fibroscan<sup> ®</sup> : A noninvasive test of liver fibrosis assessment
by: Al-Ghamdi Abdullah
Published: (2007-01-01)

The Determinants of Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
by: Chia-Yen Dai, et al.
Published: (2022-06-01)

Liver Stiffness and Steatosis Measurements with iLivTouch and FibroScan: A Comparative Study
by: Mübin Özercan, et al.
Published: (2024-08-01)